Minnesota acute graft- versus-host disease risk score predicts survival at onset of graft- versus-host disease after post-transplant cyclophosphamide prophylaxis

Haematologica. 2022 Nov 1;107(11):2748-2751. doi: 10.3324/haematol.2022.281269.
No abstract available

MeSH terms

  • Cyclophosphamide / therapeutic use
  • Graft vs Host Disease* / prevention & control
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Minnesota
  • Risk Factors

Substances

  • Cyclophosphamide